ASD-GANNet: A Generative Adversarial Network-Inspired Deep Learning Approach for the Classification of Autism Brain Disorder.

The classification of a pre-processed fMRI dataset using functional connectivity (FC)-based features is considered a challenging task because of the set of high-dimensional FC features and the small dataset size. To tackle this specific set of FC high-dimensional features and a small-sized dataset, we propose here a conditional Generative Adversarial Network (cGAN)-based dataset augmenter to first train the cGAN on computed connectivity features of NYU dataset and use the trained cGAN to generate synthetic connectivity features per category. After obtaining a sufficient number of connectivity features per category, a Multi-Head attention mechanism is used as a head for the classification.

A Novel Knowledge Distillation-Based Feature Selection for the Classification of ADHD.

Attention Deficit Hyperactivity Disorder (ADHD) is a brain disorder with characteristics such as lack of concentration, excessive fidgeting, outbursts of emotions, lack of patience, difficulty in organizing tasks, increased forgetfulness, and interrupting conversation, and it is affecting millions of people worldwide. There is, until now, not a gold standard test using which an ADHD expert can differentiate between an individual with ADHD and a healthy subject, making accurate diagnosis of ADHD a challenging task. We are proposing a Knowledge Distillation-based approach to search for discriminating features between the ADHD and healthy subjects.

A Three-Stage Teacher, Student Neural Networks and Sequential Feed Forward Selection-Based Feature Selection Approach for the Classification of Autism Spectrum Disorder.

Autism disorder, generally known as Autism Spectrum Disorder (ASD) is a brain disorder characterized by lack of communication skills, social aloofness and repetitions in the actions in the patients, which is affecting millions of the people across the globe. Accurate identification of autistic patients is considered a challenging task in the domain of brain disorder science. To address this problem, we have proposed a three-stage feature selection approach for the classification of ASD on the preprocessed Autism Brain Imaging Data Exchange (ABIDE) rs-fMRI Dataset.

Response of plasmodium vivax malaria induced thrombocytopenia to antimalarial treatment.

Background: Thrombocytopenia is often seen in the patients of malaria infected with Plasmodium vivax. We studied patients admitted in hospital having coexisting thrombocytopenia and malaria, and recorded the response to anti-malarial therapy.

Methods: In this cross-sectional descriptive study, a total of 120 patients admitted in medical ward with Plasmodium vivax malaria and co-existing thrombocytopenia were studied.

2-Anilinonicotinyl linked 2-aminobenzothiazoles and [1,2,4]triazolo[1,5-b] [1,2,4]benzothiadiazine conjugates as potential mitochondrial apoptotic inducers.

A series of N-(2-anilino-pyridyl) linked 2-amino benzothiazoles (4a-n) and [1,2,4]triazolo [1,5-b]benzothiadiazine conjugates (5a-j) have been designed, synthesized and evaluated for their antiproliferative activity. Some of these compounds (4h-k, 4n, and 5e) have exhibited potent cytotoxicity specifically against human leukemia HL-60 cell lines with IC(50) values in the range of 0.08-0.

Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?

Patients with high low-density lipoprotein cholesterol (LDLC) and asymptomatic high creatine kinase (CK) (>or=250 but <2500 IU/L, 10x the laboratory upper normal limit [UNL]) are often not started on statins or have statins stopped because of concern about myositis-rhabdomyolysis. In the current report, we prospectively examined the hypothesis that asymptomatic patients with high CK (>or=250 but <2500 IU/L) tolerate statins well at doses reducing LDLC to target, less than 100 mg/dL, without development of myalgia-myositis. We assessed outcomes of 3 groups of patients referred to us because of asymptomatic high CK (>or=250 but <2500 IU/L)--1 group (n = 29) on statins at referral and continued on statins, 1 group (n = 20) not on statins and started on statins, and 1 group (n = 19) not on statins and not given statins--all restudied 1 month after entry and then every 3 months.